Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion

• Published in: Graefe's archive for clinical and experimental ophthalmology 2009-12, Vol.247 (12), p.1635-1641
• Main Authors: Hoeh, Alexandra E., Ach, Thomas, Schaal, Karen B., Scheuerle, Alexander F., Dithmar, Stefan
• Format: Article
• Language: English
• Subjects: Aged; Angiogenesis Inhibitors - administration & dosage; Angiogenesis Inhibitors - therapeutic use; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Bevacizumab; Female; Follow-Up Studies; Humans; Injections; Macular Edema - drug therapy; Macular Edema - etiology; Macular Edema - physiopathology; Male; Medicine; Medicine & Public Health; Ophthalmology; Recurrence; Retinal Disorders; Retinal Vein Occlusion - complications; Retinal Vein Occlusion - drug therapy; Retinal Vein Occlusion - physiopathology; Retreatment; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Visual Acuity - physiology; Vitreous Body
• ISSN: 0721-832X; 1435-702X
• DOI: 10.1007/s00417-009-1151-1

Background To evaluate the long-term outcome of an OCT-guided reinjection scheme for bevacizumab treatment of macular edema (ME) due to retinal vein occlusion. Methods Patients with persistent ME (>250 μm) due to central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) received intravitreal bevacizumab 2.5 mg/0.1 ml. Visual acuity (ETDRS), ophthalmic examination and OCT were performed at baseline and at 6- to 8-week intervals. Reinjections were only performed if OCT showed persistent or recurrent ME. Results Sixty-one patients with a minimum follow-up of 25 weeks were included in this analysis. Mean follow-up was 60 ± 29 wks. In CRVO patients, central retinal thickness (CRT) decreased from 748 ± 265 µm to 372 ± 224 µm ( p